Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hepagene Therapeutics

Request full access

Chronic Hepatitis B Infection (HBV)

Pudong, ChinaFounded 2016Biotech & Life Sciences

About Hepagene Therapeutics

Hepagene Therapeutics, Inc. is a clinical-stage drug discovery and development company focused on creating innovative medicines to combat liver diseases and other life-threatening conditions. The company primarily targets non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection (HBV), and Hepatocellular Carcinoma. Hepagene operates in the biopharmaceutical market, serving patients who suffer from these severe liver conditions. The business model revolves around the discovery, development, and delivery of new therapeutic drugs, with revenue generated through the successful commercialization of these treatments. The company recently announced the dosing of the first healthy subject in a Phase I study of HPG1860, a promising drug candidate for NASH.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Apr 2021 $40M $160M Oceanpine Capital · Apricot Capital · Loyal Valley Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Hepagene Therapeutics website traffic

Latest recorded traffic for Hepagene Therapeutics is 50 monthly website visits, down 92.5% over the last three months.

Latest monthly visits50 3-month web change-92.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hepagene Therapeutics in the Pudong ecosystem

Live from Dealroom

The Hepagene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Loyal Valley Capital
  • Oceanpine Capital
  • Apricot Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Pudong HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hepagene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hepagene Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.